COPENHAGEN, Aug 10 (Reuters) - Danish drugmaker Novo Nordisk on Thursday hiked its full-year profit and sales forecast for a second time as its weight-loss and diabetes drugs flew off the shelves in the United States.
Novo now expects operating profit growth in local currencies for 2023 of between 31% and 37% and sales growth of between 27% and 33%, up from previous estimates of between 24% and 30% and between 28% and 34%, respectively.
In April, it also significantly raised its outlook.
(Reporting by Nikolaj Skydsgaard; Editing by Josephine Mason and Sharon Singleton)
